Paris, France, Monday, February 14, 2022, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that clinical data from the REFLECT Phase III trial of LUMEVOQ® gene therapy will be presented at the 48th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) in Austin, Texas (February 12-17, 2022).
Nancy J. Newman, MD, LeoDelle Jolley Professor of Ophthalmology and Neurology at the Emory University School of Medicine in Atlanta, United-States, and the International Coordinating Investigator of the REFLECT Phase III trial of LUMEVOQ®, will discuss the findings from the REFLECT trial in the context of Leber Hereditary Optic Neuropathy (LHON) natural history and the two other clinical trials RESCUE and REVERSE.
“REFLECT Trial: Efficacy and Safety of Bilateral Gene Therapy for Leber Hereditary Optic Neuropathy”
- Oral Presentation by Nancy Newman, MD
- Session: Scientific Platform Session III
- Tuesday, February 15, 2022, 11:15 – 11:30 am CDT
In addition, Benson S. Chen, MD, Department of Clinical Neurosciences, University of Cambridge and Cambridge Eye Unit, Addenbrooke’s Hospital, United Kingdom, will discuss the impact of LHON on the quality of life of patients and their families as part of the virtual session of NANOS available on demand from March 9 to May 31, 2022.
“The Impact of LHON on the Quality of Life of Patients and their Relatives”
- Poster Presentation by Benson Chen, MD
- Poster Number: 245
- Available on demand from March 9 to May 31, 2022
GenSight BiologicsChief Financial OfficerThomas Gidoin+33 (0)1 76 21 72 20
Rooney PartnersMedia RelationsJeanene Timberlake+1 646-770-8858
LifeSci AdvisorsInvestor RelationsGuillaume van Renterghem+33 (0)6 69 99 37 83
Orpheon FinanceRetail InvestorsJames Palmer+33 7 60 92 77 74